Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial

The aim of this trial is to evaluate the utility of rituximab–bendamustine (R–B) for untreated advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to identify clinical prognostic factors for FL patients receiving R–B. Patients who failed to achieve complete response/c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2021-08, Vol.114 (2), p.205-216
Hauptverfasser:	Rai, Shinya, Inoue, Hiroaki, Hanamoto, Hitoshi, Matsuda, Mitsuhiro, Maeda, Yasuhiro, Wada, Yusuke, Haeno, Takahiro, Watatani, Yosaku, Kumode, Takahiro, Hirase, Chikara, Espinoza, J. Luis, Morita, Yasuyoshi, Tanaka, Hirokazu, Tatsumi, Yoichi, Matsumura, Itaru
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell number Hematology Immunotherapy Interleukins Lymphocytes Lymphoma Lymphopenia Medical prognosis Medicine Medicine & Public Health Monoclonal antibodies Multivariate analysis Neutropenia Oncology Original Article Patients Rituximab Survival Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!